Genitourinary Cancers | Specialty

Immunotherapy Advances Offer New Hope in Bladder Cancer

August 24th 2016

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

Researchers Poised to Expand on Exciting Advancements in RCC

August 24th 2016

Mayer Fishman, MD, discusses the therapeutic landscape in renal cell carcinoma and the next steps needed to further advance the field.

Dr. Elizabeth Plimack on Consideration Regarding Nivolumab in RCC

August 23rd 2016

Second-Line Therapies for mCRPC Complicated by Drug Interactions and Dosing Issues

August 18th 2016

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.

Dr. Mohammed Haseebuddin on PD-1 Expression in RCC

August 17th 2016

Dr. Alexander I. Sankin on HHLA2 in Bladder Cancer

August 17th 2016

Dr. Fishman Discusses Available Agents to Treat Patients With RCC

August 16th 2016

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

Rio Grande Urology Expands With Gynecologic Oncology Collaboration

August 14th 2016

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

Survival Improved With Surgery/Targeted Therapy Combo in Renal Cell Carcinoma

August 13th 2016

Patients with renal cancer who underwent cytoreductive nephrectomy and targeted therapy had improved survival compared with patients who did not undergo the surgery.

Expert Explores Next Steps With "Game Changer" Atezolizumab in Bladder Cancer

August 11th 2016

Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.

Immunotherapy Advances Again Propel Progress in GU Malignancies

August 11th 2016

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

In Politics, Not Everybody Works Well Together

August 11th 2016

The lack of cooperation and inability to compromise, at the expense of our country’s best interests, has resulted in gridlock.

Dr. Michael L. Blute on Partial Nephrectomy Rates in RCC

August 10th 2016

Caring for US Veterans Helped Lead Iraqi Immigrant to Develop Prostate Cancer Advances

August 6th 2016

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

Dr. David F. McDermott on Nivolumab in RCC

August 5th 2016

New Checkpoint Target Emerges in Bladder Cancer

August 4th 2016

Alexander I. Sankin, MD, discusses how bladder cancer researchers are looking beyond PD-L1 and CTLA-4 to HHLA2, a potentially druggable new checkpoint target.

Dr. Peter O'Donnell on Atezolizumab and IMvigor 210

August 2nd 2016

With Its Long History and Pioneering Spirit, Urology of Virginia Faces a Changing Landscape

July 31st 2016

Michael Fabrizio, MD, and Dana Adams, COO, provide their perspective on the challenges that urology practices face today.

CHMP Grants Positive Opinion for Cabozantinib in Renal Cell Carcinoma

July 22nd 2016

Cabozantinib (Cabometyx) has received a positive recommendation from the EMA's Committee for Medicinal Products for Human Use for use as treatment for patients with advanced renal cell carcinoma after the failure of VEGF-targeted therapy.

CHMP Adopts Positive Opinion for Lenvatinib/Everolimus Combo in RCC

July 22nd 2016

The CHMP has recommended the approval of lenvatinib in combination with everolimus for patients with advanced renal cell carcinoma following one prior VEGF-targeted therapy.